Mobile Chat Messaging for Preventing Smoking Relapse Amid the COVID-19 Pandemic: A Pilot Randomized Controlled Trial

Tzu Tsun Luk, Yee Tak Derek Cheung, Helen Ching-Han Chan, Patrick Wai-Yin Fok, Kin Sang Ho, Chu Dik Sze, Tai Hing Lam, Man Ping Wang, Tzu Tsun Luk, Yee Tak Derek Cheung, Helen Ching-Han Chan, Patrick Wai-Yin Fok, Kin Sang Ho, Chu Dik Sze, Tai Hing Lam, Man Ping Wang

Abstract

Introduction: The ongoing COVID-19 pandemic had reduced access to traditional, in-person smoking cessation treatment. We examined the feasibility, acceptability, and potential effectiveness of mobile chat messaging in preventing smoking relapse in smokers who have recently quit smoking.

Methods: In this assessor-blinded, pilot randomized controlled trial in five cessation clinics, we recruited adult daily smokers who had been receiving cessation treatments and abstained for 3 to 30 days. The intervention group received real-time, personalized chat messaging on relapse prevention via WhatsApp for 3 months. The control group received generic text messaging on the harms of smoking and benefits of quitting for 3 months. The primary outcome was carbon monoxide-validated abstinence at 6 months post-treatment initiation. The trial was registered with ClinicalTrials.gov (NCT04409496).

Results: From June to July 2020, 108 of 130 (83%) eligible subjects were randomized to the intervention (N = 54) or control (N = 54) groups. The retention rate was 93% at 3 months (end of treatment) and 85% at 6 months. In the intervention group, 80% of participants responded to the chat messages at least once; 43% continuously engaged with the intervention over the 3-month intervention period. By intention-to-treat, validated abstinence at 6 months was higher in the intervention than control group (31% vs. 22%), with a relative risk of 1.72 (95% CI = 0.91% to 3.23%; p = .09) after adjusting for pre-quit nicotine dependence, duration of abstinence, and cessation treatment at baseline.

Conclusions: This pilot trial showed the feasibility and acceptability of mobile chat messaging for relapse prevention with preliminary evidence on its effectiveness in increasing validated abstinence.

Implications: Smoking relapse is the most likely outcome of smoking cessation attempts and an undertreated problem. This pilot trial showed the feasibility and acceptability of personalized chat messaging via WhatsApp for relapse prevention in recent abstainers amid the COVID-19 pandemic. The higher carbon monoxide-validated abstinence rate in participants who received chat messaging than controls showed preliminary evidence on the effectiveness of the intervention. Fully powered trials are warranted to test the intervention.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
CONSORT diagram. aSome subjects had more than two reasons for exclusion.

References

    1. Jackson SE, McGowan JA, Ubhi HK, et al. . Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. Addiction. 2019;114(5):787–797.
    1. Livingstone‐Banks J, Norris E, Hartmann-Boyce J, et al. . Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019;2019(10):CD003999.
    1. Whittaker R, McRobbie H, Bullen C, et al. . Mobile phone text messaging and app‐based interventions for smoking cessation. Cochrane Database Syst Rev. 2019;10(10):CD006611.
    1. Cheung YTD, Chan CH, Lai CK, et al. . Using WhatsApp and Facebook online social groups for smoking relapse prevention for recent quitters: A pilot pragmatic cluster randomized controlled trial. J Med Internet Res. 2015;17(10):e238.
    1. Giordano V, Koch H, Godoy-Santos A, et al. . WhatsApp messenger as an adjunctive tool for telemedicine: An overview. Interact J Med Res. 2017;6(2):e11.
    1. Statista. Penetration Rate of Leading Social Networks in Hong Kong as of 3rd Quarter 2020; 2021. . Accessed 24 January 2022.
    1. Luk TT, Wong SW, Lee JJ, et al. . Exploring community smokers’ perspectives for developing a chat-based smoking cessation intervention delivered through mobile instant messaging: Qualitative study. JMIR MHealth UHealth. 2019;7(1):e11954.
    1. Wang MP, Luk TT, Wu Y, et al. . Chat-based instant messaging support integrated with brief intervention for smoking cessation: A community-based, pragmatic, cluster-randomized controlled trial. Lancet Digit Health. 2019;1(4):e183–e192.
    1. World Health Organization. Smoking and COVID-19: Scientific Brief June 2020. . Accessed 24 January 2022.
    1. Li Y, Luk TT, Wu Y, et al. . High perceived susceptibility to and severity of COVID-19 in smokers are associated with quitting-related behaviors. Int J Environ Res Public Health. 2021;18(20):10894.
    1. Luk TT, Zhao S, Weng X, et al. . Exposure to health misinformation about COVID-19 and increased tobacco and alcohol use: A population-based survey in Hong Kong. Tob Control. 2021;30:653–659.
    1. Patwardhan P. COVID-19: Risk of increase in smoking rates among England’s 6 million smokers and relapse among England’s 11 million ex-smokers. BJGP Open. 2020;4(2):bjgpopen20X101067. doi:10.3399/bjgpopen20X101067.
    1. Chan S, Leung Y, Chan C, Lam T.. An Evaluative Study of the Integrated Smoking Cessation Services of TungWah Group of Hospitals. Hong Kong SAR: Tung Wah Group of Hospitals; 2011.
    1. Eldridge SM, Chan CL, Campbell MJ, et al. . CONSORT 2010 statement: Extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.
    1. Michie S, Hyder N, Walia A, West R. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav. 2011;36(4):315–319.
    1. Piper ME, Cook JW, Schlam TR, et al. . A randomized controlled trial of an optimized smoking treatment delivered in primary care. Ann Behav Med. 2018;52(10):854–864.
    1. Cha S, Ganz O, Cohn AM, Ehlke SJ, Graham AL. Feasibility of biochemical verification in a web-based smoking cessation study. Addict Behav. 2017;73:204–208.
    1. Piper ME, Bullen C, Krishnan-Sarin S, et al. . Defining and measuring abstinence in clinical trials of smoking cessation interventions: An updated review. Nicotine Tob Res. 2020;22(7):1098–1106.
    1. Cropsey KL, Trent LR, Clark CB, et al. . How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference. Nicotine Tob Res. 2014;16(10):1348–1355.
    1. Leung DY, Chan SS, Lau C, Wong V, Lam T. An evaluation of the psychometric properties of the Smoking Self-Efficacy Questionnaire (SEQ-12) among Chinese cardiac patients who smoke. Nicotine Tob Res. 2008;10(8):1311–1318.
    1. Yu X, Xiao D, Li B, et al. . Evaluation of the Chinese versions of the Minnesota nicotine withdrawal scale and the questionnaire on smoking urges-brief. Nicotine Tob Res. 2010;12(6):630–634.
    1. Thabane L, Ma J, Chu R, et al. . A tutorial on pilot studies: The what, why and how. BMC Med Res Methodol. 2010;10(1):1.
    1. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706.
    1. Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: An assessment of 12 outcomes from 8 studies. Trials 2014;15(1):139.
    1. Lee PH. Covariate adjustments in randomized controlled trials increased study power and reduced biasedness of effect size estimation. J Clin Epidemiol. 2016;76:137–146.
    1. Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: A systematic review. Addiction 2011;106(12):2110–2121.
    1. Ashare RL, Wileyto EP, Perkins KA, Schnoll RA. The first 7 days of a quit attempt predicts relapse: Validation of a measure for screening medications for nicotine dependence. J Addict Med. 2013;7(4):249–254.
    1. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta‐analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329.
    1. Zeng EY, Heffner JL, Copeland WK, Mull KE, Bricker JB. Get with the program: Adherence to a smartphone app for smoking cessation. Addict Behav. 2016;63:120–124.
    1. Hoeppner BB, Hoeppner SS, Abroms LC. How do text‐messaging smoking cessation interventions confer benefit? A multiple mediation analysis of Text2Quit. Addiction 2017;112(4):673–682.
    1. Grummon AH, Hall MG, Mitchell CG, et al. . Reactions to messages about smoking, vaping and COVID-19: Two national experiments. Tob Control. 2020. doi:10.1136/tobaccocontrol-2020-055956.
    1. Reitsma MB, Kendrick PJ, Ababneh E, et al. . Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021;397(10292):2337–2360.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir